Patients with chronic hepatitis C patients and patients with type C compensated cirrhosis
Conditions
Interventions
Case of chronic hepatitis C of genotype 1 or genotype 2: Three tablets once daily (300 mg as Glecaprevir and 120 mg as Pibrentasvir), orally administered after meals. The administration period is 8 w
Sponsors
Nippon Medical School Chiba Hokusoh Hospital
National Hospital Organization Kyushu Medical Center St. Marianna University School of Medicine Shinmatusdo Central General Hospital Nippon Medical School Nippon Medical School Musashi Kosugi Hospital Otakanomori Hospital Tokyo Metropolitan Bokutoh Hospital Kitasato University School of Medicine Takamatsu Red Cross Hospital Ogaki Municipal Hospital Kagawa Prefectural Central Hospital Kikkoman General Hospital Tokyo Medical University Ibaraki Medical Center Osaka Medical College Na
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who treated with Glecaprevir and Pibrentasvir combination therapy.
Exclusion criteria
Exclusion criteria: 1.History of allergy to Glecaprevir / Pibrentasvir 2.Severe liver dysfunction 3.pregnant woman or lactating mother 4.Hepatocellular carcinoma, or other malignant tumor. 5.severe depression 6.Judged by investigator not to be appropriate for inclusion in this study 7.Receiving contraindicated drugs for Glecaprevir and Pibrentasvir combined therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SVR 12 rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in serum HCV RNA during treatment and follow-up duration 2. Change in hematological and biochemical test during treatment and follow-up duration 3. Change in Mac-2 Binding Protein,hyaluronic acid, type IV collagen,gamma globulin during treatment and follow-up duration. 4. Drug concentration after administration in hemodialysis patients. | — |
Countries
Japan
Contacts
Public ContactMasanori Atsukawa
Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology
Outcome results
None listed